Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02431923 · ClinicalTrials.gov registry record
Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 4,043
- Enrollment target
NCT02431923 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 4,043 participants.
The verdict
NCT02431923 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 4,043 participants
- Enrollment target
Study Summary
Background: \- Ebola is a lethal disease. A lot is still unknown about Ebola and its long-term effects. Researchers want to learn what ill health conditions Ebola survivors have. They want to learn if Ebola survivors can infect others in their household through close contact. They also want to learn if Ebola survivors are immune from getting Ebola again. To learn these things, they want to follow people in Liberia for 5 years. Objectives: \- To learn how Ebola affects the health of survivors and the people they live with. Eligibility: \- People in Liberia who had Ebola in the past 2 years, who share a household with someone who had Ebola, or who got ill and went to an Ebola Treatment Unit but were sent home because they did not have Ebola. Design: * Participants will be screened with family illness history, physical exam, and blood tests. They may have an eye exam. * Ebola survivors and those who went to a Treatment Unit but did not have Ebola will visit a clinic at 3, 6, and 12 months, then every 6 months for 5 years. At each visit, they will repeat the screening tests. * Participants who live with someone who had Ebola will have only the screening visit. But they may be asked to return for follow-up visits. These visits will help researchers learn more about the differences between those who have had Ebola and those who have not. * Participants brought to the NIH Clinical Center will have documentation of positive Ebola virus PCR and a clinical syndrome compatible with acute EVD. * The study will last 5 years.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,043 participants |
| Start Date | 2017-12-02 |
| Est. Completion | 2021-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02431923
The ClinicalTrials.gov registry entry for NCT02431923 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4,043 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02431923 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02431923 about?
NCT02431923 is a clinical study titled "Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up". Background: \- Ebola is a lethal disease. A lot is still unknown about Ebola and its long-term effects. Researchers want to learn what ill health conditions Ebola survivors have. They want to learn if Ebola survivors can infect others in their household through close contact. They also want to lear...
What is the current status of trial NCT02431923?
This trial is currently completed. The enrollment target is 4,043 participants. The study started on 2017-12-02. Estimated completion is 2021-04-30.
Who is sponsoring clinical trial NCT02431923?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.